Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expressionby anti-tumor agents GAP31 and MAP30
Autore:
Lee-Huang, S; Huang, PL; Sun, YT; Chen, HC; Kung, HF; Huang, PL; Murphy, WJ;
Indirizzi:
NCI, Frederick Canc Res & Dev Ctr, SAIC, Frederick, MD 21702 USA NCI Frederick MD USA 21702 c Res & Dev Ctr, SAIC, Frederick, MD 21702 USA NYU, Sch Med, Dept Biochem, New York, NY 10016 USA NYU New York NY USA 10016 , Sch Med, Dept Biochem, New York, NY 10016 USA NICHHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA NICHHD Bethesda MD USA 20892 prod Res Branch, NIH, Bethesda, MD 20892 USA NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Physiol, Frederick, MD 21701 USA NCI Frederick MD USA 21701 , Lab Biochem Physiol, Frederick, MD 21701 USA Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA Massachusetts Gen Hosp Boston MA USA 02114 Dept Med, Boston, MA 02114 USA Harvard Univ, Sch Med, Boston, MA 02114 USA Harvard Univ Boston MA USA 02114 vard Univ, Sch Med, Boston, MA 02114 USA
Titolo Testata:
ANTICANCER RESEARCH
fascicolo: 2A, volume: 20, anno: 2000,
pagine: 653 - 659
SICI:
0250-7005(200003/04)20:2A<653:IOMHBT>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-FACTOR RECEPTOR; CANCER; AMPLIFICATION; RESISTANCE; GAP-31; MAP-30; DNA;
Keywords:
breast carcinoma; anti-tumor; xenograft; in vitro;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Murphy, WJ NCI, Frederick Canc Res & Dev Ctr, SAIC, Bldg 567,Room 210, Frederick, MD 21702 USA NCI Bldg 567,Room 210 Frederick MD USA 21702 rick, MD 21702 USA
Citazione:
S. Lee-Huang et al., "Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expressionby anti-tumor agents GAP31 and MAP30", ANTICANC R, 20(2A), 2000, pp. 653-659

Abstract

GAP31 (Gelonium protein of 31 kDa) and MAP30 (Momordica protein of 30 kDa)are agents isolated from the medicinal plants Gelonium multiflorum and Momordica charantia, respectively. The current study was conducted to investigate the efficacy of GAP31 and MAP30 on estrogen-independent and highly metastatic human breast tumor MDA-MB-231 both in vitro and in vivo. The effect of these agents on the expression of breast tumor antigen HER2 (also known as neu or as c-erbB 2) was also examined. Treatment of MDA-MB-231 breast cancer cells with GAP31 and MAP30 resulted in inhibition of cancer cell proliferation as well as inhibition of the expression of HER2 gene in vitro. When MDA-MB-231 human breast cancer cells were transferred into SCID mice, themice developed extensive metastases and all mice succumbed to tumor by day46. Treatment of the human breast cancer bearing SCID mice with GAP32 or MAP30 at 10 mu g/injection EOD for 10 injections resulted in significant increases in survival, with 20-25% of the mice remaining tumor free for 96 days. Thus antitumor agents GAP31 and MAP30 are effective against human br east cancer MDA-MB-231 in vitro and in vivo. There agents may therefore be of potential therapeutic use against breast carcinomas.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 16:05:54